Bolstered by recent CE Mark approval, Bausch + Lomb Corporation has officially launched its enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union. enVista Aspire combines Intermediate Optimized optics, which are designed for a broader depth of focus,* with the enVista platform’s benefits to address current vision needs.

“Surgeons around the world have long known the benefits of the enVista platform,” stated Luc Bonnefoy, president, Surgical, Bausch + Lomb. “In the U.S., where enVista Aspire is currently available, surgeons and their patients appreciate the features of these monofocal lenses that are designed for a broader depth of focus,* and we look forward to offering that feature in Europe as part of our IOL portfolio.”

Unlike conventional spherical monofocal IOLs and lower-order aspheric IOLs, the enVista Aspire monofocal optics allow for a range of vision beyond one focal point, according to Bausch + Lomb. Like enVista MX60E, enVista Aspire offers a glistening-free optic material and controlled, efficient unfolding through Bausch + Lomb’s proprietary StableFlex Technology, which aids optic recovery.

For patients with astigmatism, enVista Aspire Toric IOLs provide a proven option for treatment of their astigmatism during cataract surgery. Featuring a +0.90 cylinder design, the enVista toric IOL platform can treat less than one diopter of astigmatism at the corneal plane. The AccuSet haptic design enables exceptional rotational stability, an important attribute for toric lenses.

The enVista Aspire hydrophobic acrylic IOL (non-preloaded model EA) is indicated for primary implantation in the eye’s capsular bag in adult patients to correct aphakia after removing a cataractous lens.

The Aspire IOL uses an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter to slightly extend the depth of focus. However, clinically meaningful extension of the depth of focus has not been demonstrated in clinical trials.

Neither the safety and effectiveness, nor the effects of the Aspire IOL optical design on depth of focus, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have been evaluated clinically.

Bausch + Lomb’s portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing, and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, N.J.

* Based on optical bench testing. MTF study in IS02 model cornea, comparison of MX60E and enVista Aspire.